High-dose therapy and autologous stem cell transplantation for children with HIV-associated non-Hodgkin lymphoma
Publisher DOI
PubMed ID
16685736
Abstract
In contrast to adults, autologous stem cell transplantation (ASCT) as part of the salvage strategy after high-dose chemo/radiotherapy in human immunodeficiency virus (HIV) related Non-Hodgkin lymphoma (NHL) is not yet established for children. We report on a 13-year patient with congenital HIV infection and refractory Burkitt lymphoma, who was successfully treated by high-dose therapy (HDT) including rituximab followed by ASCT. After 26 months follow-up the patient remains in complete remission and his HIV parameters have normalized with continued highly active antiretroviral therapy (HAART). HIV infection may no longer exclude children from ASCT as part of salvage therapy. Pediatr Blood Cancer (c) 2006 Wiley-Liss, Inc.
Date Issued
2006
Publication Type
Article
Language(s)
en
Author(s)
Lüthy, Annette Ridolfi |
Additional Credits
Journal
Pediatric blood & cancer
Publisher
Wiley-Liss
ISSN
1545-5009
ISBN
16685736
Access(Rights)
metadata.only